Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR.

J Clin Oncol. 2005 Sep 1;23(25):5943-9.

PMID:
16135465
2.

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group..

Gynecol Oncol. 2009 Nov;115(2):215-20. doi: 10.1016/j.ygyno.2009.07.023. Epub 2009 Aug 26.

PMID:
19712963
3.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA.

Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15. Epub 2006 Jun 9.

PMID:
16763792
4.

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.

J Clin Oncol. 2008 Dec 10;26(35):5761-6. doi: 10.1200/JCO.2008.17.0282. Epub 2008 Nov 10.

PMID:
19001330
5.

A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.

Rose PG, Smrekar M, Haba P, Visser C, Beeler JF.

Gynecol Oncol. 2005 Dec;99(3):714-9. Epub 2005 Aug 19.

PMID:
16112177
6.

A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.

Leiser AL, Maluf FC, Chi DS, Sabbatini P, Hensley ML, Schwartz L, Venkatraman E, Spriggs D, Aghajanian C.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):379-86.

PMID:
17362316
7.

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC.

J Clin Oncol. 2004 Dec 1;22(23):4804-9. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570082
8.

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.

Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.

Gynecol Oncol. 2009 Dec;115(3):377-81. doi: 10.1016/j.ygyno.2009.08.021. Epub 2009 Oct 1.

PMID:
19800107
9.

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.

Ramirez PT, Landen CN Jr, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM.

Gynecol Oncol. 2008 Jan;108(1):68-71. Epub 2007 Oct 1.

PMID:
17905421
10.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.

J Clin Oncol. 2004 Jun 1;22(11):2108-21.

PMID:
15169797
11.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

PMID:
16418495
12.

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Covens A, Blessing J, Bender D, Mannel R, Morgan M; Gynecologic Oncology Group..

Gynecol Oncol. 2006 Mar;100(3):586-90. Epub 2005 Oct 24.

PMID:
16249022
13.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E; National Cancer Institute of Canada Clinical Trials Group..

J Clin Oncol. 2007 Apr 20;25(12):1570-5. Epub 2007 Mar 12.

PMID:
17353550
14.
15.

A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.

Sehouli J, Alvarez AM, Manouchehrpour S, Ghatage P, Szczylik C, Zimmermann A, Bauknecht T, Look KY, Oskay-Ă–ezcelik G.

Gynecol Oncol. 2012 Feb;124(2):205-9. doi: 10.1016/j.ygyno.2011.09.007. Epub 2011 Nov 1.

PMID:
22044606
16.

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

Kimball KJ, Numnum TM, Kirby TO, Zamboni WC, Estes JM, Barnes MN, Matei DE, Koch KM, Alvarez RD.

Gynecol Oncol. 2008 Oct;111(1):95-101. doi: 10.1016/j.ygyno.2008.07.001. Epub 2008 Aug 8.

PMID:
18692224
17.

Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.

Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N.

Gynecol Oncol. 2007 Jan;104(1):114-9. Epub 2006 Sep 7.

PMID:
16959305
18.

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.

PMID:
22635029
19.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.

Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G.

Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7.

PMID:
20054549
20.

Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.

Strauss HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Koelbl H.

Gynecol Oncol. 2007 Mar;104(3):612-6. Epub 2006 Oct 27.

PMID:
17069876

Supplemental Content

Support Center